TP53 and myelodysplastic syndrome: Sallman et al. demonstrated that MDS and secondary AML patients with TP53 mutations exhibit elevated PD-L1 expression in HSCs, which is driven by the upregulation of MYC and the downregulation of MYC’s negative regulator miR-34a.